Coverage Period: June 15 - June 21, 2026
In the third week of June 2026, global medical device and MedTech news highlighted several key developments: a proposed expansion of TAVR reimbursement in the U.S., thrombectomy devices in the neurovascular field, advancements in minimally and non-invasive treatment technologies, manufacturing investments, and the initiation of clinical trials.
In the medical device business, a comprehensive market strategy is crucial, encompassing not only regulatory approval but also insurance reimbursement, clinical evidence, manufacturing and supply systems, and post-market safety. This week's news reveals multiple critical points that influence competitiveness in the global market.
1. CMS Proposes Expansion of Medicare Coverage for TAVR
The U.S. CMS has published a proposed revision to the National Coverage Determination for Transcatheter Aortic Valve Replacement (TAVR/TAVI).
In addition to revising the coverage conditions for symptomatic severe aortic stenosis, this proposal indicates a direction to cover asymptomatic severe aortic stenosis under certain conditions.
While TAVR is already widely adopted as a primary treatment in the field of structural heart disease, changes in insurance coverage scope and facility requirements significantly impact market size. This is a typical example where, for medical devices, not only regulatory approval but also reimbursement and coverage conditions dictate the speed of product adoption.
Source: CMS - Proposed Decision Memo for TAVR
2. Penumbra Obtains European CE Mark for Thunderbolt Thrombectomy System
Penumbra has obtained the European CE Mark for its Thunderbolt Thrombectomy System, intended for acute ischemic stroke.
Thunderbolt expands the company's computer-assisted vacuum thrombectomy (CAVT) technology into the neurovascular field. Following FDA clearance in the United States, this marks a step forward for its expansion into the European market.
In stroke treatment, key factors include the time from onset to treatment, the rate of clot removal, device operability, and vascular accessibility. This CE Mark acquisition suggests that competition in aspiration thrombectomy and automation technologies within the neurovascular domain is likely to intensify further.
Source: Penumbra - Thunderbolt Thrombectomy System CE Mark
3. Johnson & Johnson Invests Over $1 Billion in U.S. Contact Lens Manufacturing
Johnson & Johnson announced an investment of over $1 billion in Jacksonville, Florida, to enhance its manufacturing, packaging, and distribution capabilities for contact lenses, primarily under the ACUVUE brand.
In the medical device industry, decentralization of manufacturing sites, strengthening domestic production bases, and ensuring supply stability have become critical themes in recent years. Particularly for mass-produced medical devices like contact lenses, manufacturing capacity itself is a key competitive advantage.
This investment is positioned not merely as an expansion of facilities but also as a strengthening of the supply chain and a response to long-term demand growth.
Source: Johnson & Johnson - Press Releases
4. AngioDynamics Receives FDA IDE Approval for NanoKnife BPH Clinical Trial
AngioDynamics has obtained FDA IDE approval to initiate the RELIEF feasibility study for its NanoKnife system, which uses irreversible electroporation, targeting lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).
The NanoKnife, a non-thermal ablation technology, has primarily garnered attention in the oncology field until now. Its expansion into the BPH domain is noteworthy as a lifecycle strategy that extends existing technology to a new disease area.
For medical device companies, expanding the indications of an existing platform technology is an effective way to broaden market opportunities while mitigating development risks. However, for new indications, clinical trial design, endpoints, comparison with existing treatments, and reimbursement strategies become crucial.
Source: AngioDynamics - FDA IDE Approval for RELIEF Feasibility Study
5. Sonire Therapeutics Receives NEDO Support for HIFU Cancer Treatment System
Sonire Therapeutics, a company originating from Japan, has reportedly received support through NEDO's Deep-Tech Startups Support Program to commercialize its ultrasound-guided HIFU treatment system.
The target is a non-invasive treatment platform for solid tumors, including pancreatic cancer. HIFU is anticipated as a non-invasive approach that differs from surgical procedures and percutaneous treatments.
However, to commercialize it as a medical device, key factors include the reproducibility of treatment effects, irradiation accuracy under image guidance, safety, clinical trial design, and reimbursement strategy. Particularly in the field of cancer treatment, clearly defining its positioning relative to existing treatments will be crucial for market entry.
Source: BioSpace - Sonire Therapeutics NEDO Funding
6. FDA CDRH Updates Recall and Safety Information
The FDA CDRH has updated information regarding medical device recalls, safety notifications, supply shortages, and lists of AI-powered medical devices, among other things.
For medical device manufacturers, recall and safety information reaffirms the importance of quality systems, post-market surveillance, complaint handling, and change control.
Risk management is required at each stage—design, manufacturing, labeling, instructions for use, and post-market surveillance—especially for devices such as catheters, reprocessed devices, implants, and AI-powered medical devices. Companies operating globally need a system to continuously monitor safety information from regulatory authorities in each country.
Source: FDA CDRH - New and Updates
Practical Implications
From this week's news, there are three major important implications for medical device companies.
Reimbursement Strategy is Essential for Post-Approval Market Formation
As demonstrated by TAVR cases, market expansion for medical devices does not occur simply with regulatory approval. Insurance coverage, facility requirements, clinical evidence requirements, and the evaluation within medical fee schedules significantly impact product penetration.
Especially for high-cost medical devices and novel treatment technologies, it is crucial to design a strategy from the early stages of development that anticipates reimbursement and coverage.
Advances in the Development of Minimally Invasive and Non-Invasive Treatments
Investment and clinical development are progressing for technologies that aim for therapeutic effects while reducing patient burden, such as thrombectomy devices, irreversible electroporation, and HIFU.
For these technologies, it is crucial not only to demonstrate that they are "minimally invasive" but also to show their effectiveness, safety, procedure time, and health economics compared to existing treatments.
Manufacturing and Supply System is Also Part of Competitiveness
Johnson & Johnson's substantial investment demonstrates that manufacturing capability and supply stability continue to be critical in the medical device business.
Especially for medical devices with global reach, regulatory approval, QMS, manufacturing capability, logistics, and supply continuity must be managed as an integrated whole.
Summary
In the medical device news for the third week of June 2026, we saw developments such as the proposed expansion of TAVR reimbursement in the US, Penumbra's thrombectomy devices expanding in Europe, Johnson & Johnson's large-scale manufacturing investment, and progress in minimally invasive and non-invasive treatment technologies by AngioDynamics and Sonire Therapeutics.
For medical device companies, designing not only regulatory approval but also clinical evidence, insurance reimbursement, manufacturing systems, and post-market safety as an integrated whole is crucial for competitiveness in the global market.
MK Consulting provides practical support for market entry into Japan, medical device regulatory applications, clinical evaluation, insurance reimbursement, and interactions with PMDA and Registered Certification Bodies. We also offer initial consultations for overseas medical device manufacturers expanding into Japan and Japanese companies expanding overseas.